Cargando…

Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis

BACKGROUND: Axial spondyloarthritis (axSpA) is associated with an increased risk of cardiovascular disease. We aimed to evaluate the effect of tumor necrosis factor inhibitors (TNFis) on the risk of cardiovascular disease in patients with axSpA. METHODS: This retrospective study included 450 patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Oh Chan, Park, Min-Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190158/ https://www.ncbi.nlm.nih.gov/pubmed/35698171 http://dx.doi.org/10.1186/s13075-022-02836-4

Ejemplares similares

Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis
por: Kwon, Oh Chan, et al.
Publicado: (2023)

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
por: Micheroli, Raphael, et al.
Publicado: (2017)

Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study
por: Park, Jun Won, et al.
Publicado: (2019)

Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors
por: Nissen, Michael J., et al.
Publicado: (2021)

Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
por: Yahya, Fariz, et al.
Publicado: (2019)

The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
por: Toussirot, Eric
Publicado: (2021)

Disease course of non-radiographic axial spondyloarthritis: Data from a long-term retrospective observational cohort
por: Kwon, Oh Chan, et al.
Publicado: (2023)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019)

Selection of X-ray versus magnetic resonance imaging as a first-line imaging modality for diagnosing axial spondyloarthritis
por: Chan Kwon, Oh, et al.
Publicado: (2022)

Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
por: Huang, Yupeng, et al.
Publicado: (2020)

Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

A Review on the Effect of Tumor Necrosis Factor Inhibitors on Structural Progression in Early Axial Spondyloarthritis Using Magnetic Resonance Imaging
por: Li, Ko-Jen, et al.
Publicado: (2019)

Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis
por: Pedersen, Susanne J, et al.
Publicado: (2014)

Cardiovascular risk in axial spondyloarthritis—a systematic review
por: Hintenberger, Rainer, et al.
Publicado: (2023)

Peripheral Enthesitis Detected by Ultrasonography in Patients With Axial Spondyloarthritis—Anatomical Distribution, Morphology, and Response to Tumor Necrosis Factor-Inhibitor Therapy
por: Seven, Sengul, et al.
Publicado: (2020)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis
por: Genre, Fernanda, et al.
Publicado: (2020)

Measurement of pre‐treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients
por: Peng, Fei, et al.
Publicado: (2022)

A cluster analysis of patients with axial spondyloarthritis using tumour necrosis factor alpha inhibitors based on clinical characteristics
por: Lee, Seulkee, et al.
Publicado: (2021)

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
por: Michielsens, Celia A J, et al.
Publicado: (2021)

Tumour necrosis factor inhibitor tapering in patients with ankylosing spondylitis at low disease activity: factors associated with flare
por: Kwon, Oh Chan, et al.
Publicado: (2021)

Korean treatment recommendations for patients with axial spondyloarthritis
por: Seo, Mi Ryoung, et al.
Publicado: (2023)

Korean treatment recommendations for patients with axial spondyloarthritis
por: Seo, Mi Ryoung, et al.
Publicado: (2023)

Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study
por: Rueda-Gotor, Javier, et al.
Publicado: (2021)

Predictors of Assessment of Spondyloarthritis International Society (ASAS) Health Index in Axial Spondyloarthritis and Comparison of ASAS Health Index between Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
por: Min, Hong Ki, et al.
Publicado: (2019)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
por: Al Arashi, Wala, et al.
Publicado: (2018)

Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
por: Torgutalp, Murat, et al.
Publicado: (2022)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2022)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
por: Sebastian, Agata, et al.
Publicado: (2017)

Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors
por: Moz, Stefania, et al.
Publicado: (2017)

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort: reply
por: Yahya, Fariz, et al.
Publicado: (2018)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis
por: Ladehesa-Pineda, María Lourdes, et al.
Publicado: (2020)

Cytokine profiles in axial spondyloarthritis
por: Madej, Marta, et al.
Publicado: (2015)

Patient Burden of Axial Spondyloarthritis
por: Strand, Vibeke, et al.
Publicado: (2017)

Axial Spondyloarthritis and Cigarette Smoking
por: Kaut, Irène Kona, et al.
Publicado: (2017)

Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020)

Genetics and the axial spondyloarthritis spectrum
por: Brown, Matthew A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hq79vo55lrk2b1pafuj25nirfo